Blarcamesine Shows Promising Results in Phase 2 Extension Study: Anavex Life Sciences

Anavex Life Sciences, OR Anavex, a leading biopharmaceutical company, has reported positive findings from the 48-week, open-label extension of their phase 2 study of blarcamesine in patients with Parkinson’s disease dementia (PDD). The investigational agent, also known as ANAVEX2-73, demonstrated favorable safety and efficacy outcomes, meeting its primary and secondary objectives in this cohort of […]